{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:09Z","timestamp":1790717169667,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970639"],"award-info":[{"award-number":["81970639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82151320"],"award-info":[{"award-number":["82151320"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016334","name":"Jiangsu Province Hospital","doi-asserted-by":"publisher","award":["JSPH-MC-2022-18"],"award-info":[{"award-number":["JSPH-MC-2022-18"]}],"id":[{"id":"10.13039\/501100016334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"publisher","award":["JSDW202206"],"award-info":[{"award-number":["JSDW202206"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xkme.2026.101334","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:19:37Z","timestamp":1773505177000},"page":"101334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interleukin-17 Inhibitors and the Potential Association of Systemic Lupus Erythematosus"],"prefix":"10.1016","volume":"8","author":[{"given":"Lingling","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4874-9171","authenticated-orcid":false,"given":"Buyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9919","key":"10.1016\/j.xkme.2026.101334_bib1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(14)60397-4","article-title":"Secukinumab for ankylosing spondylitis","volume":"383","author":"Abate","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.xkme.2026.101334_bib2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.xkme.2026.101334_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xkme.2026.101334_bib4","article-title":"Axial spondyloarthritis: new advances in diagnosis and management","volume":"372","author":"Ritchlin","year":"2021","journal-title":"BMJ"},{"issue":"10163","key":"10.1016\/j.xkme.2026.101334_bib5","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.xkme.2026.101334_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017","volume":"84","author":"Mehrmal","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"9999","key":"10.1016\/j.xkme.2026.101334_bib7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"10217","key":"10.1016\/j.xkme.2026.101334_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.xkme.2026.101334_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101334_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00105-017-4071-8","article-title":"Secukinumab-induzierter subakut-kutaner Lupus erythematodes [Secukinumab-induced subacute-cutaneous lupus erythematosus]","volume":"69","author":"Wehrmann","year":"2018","journal-title":"Hautarzt"},{"issue":"4","key":"10.1016\/j.xkme.2026.101334_bib11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jdcr.2020.02.013","article-title":"Secukinumab-induced chronic discoid lupus erythematosus","volume":"6","author":"Chatzimichail","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.xkme.2026.101334_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13417","article-title":"Secukinumab-induced subacute cutaneous lupus erythematosus","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol Ther"},{"issue":"8 suppl","key":"10.1016\/j.xkme.2026.101334_bib13","doi-asserted-by":"crossref","first-page":"S753","DOI":"10.1097\/RHU.0000000000001511","article-title":"Secukinumab-induced lupus erythematosus: a case report and literature review","volume":"27","author":"Kaler","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101334_bib14","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1093\/rheumatology\/keab918","article-title":"Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis","volume":"61","author":"Koller-Smith","year":"2022","journal-title":"Rheumatol (Oxford)"},{"issue":"3","key":"10.1016\/j.xkme.2026.101334_bib15","first-page":"265","article-title":"Secukinumab-induced systemic lupus erythematosus in psoriatic arthritis","volume":"2","author":"\u00c1vila-Ribeiro","year":"2023","journal-title":"ARP Rheumatol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101334_bib16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/09612033241242698","article-title":"Membranous lupus nephritis secondary to secukinumab therapy: a case report and literature review","volume":"33","author":"Zhou","year":"2024","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.xkme.2026.101334_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/ced.14583","article-title":"Brodalumab-induced subacute cutaneous lupus erythematosus","volume":"46","author":"Ang","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101334_bib18","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1111\/ajd.12811","article-title":"Ixekizumab-treatment-emergent photosensitive cutaneous eruption","volume":"59","author":"Anthony","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101334_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.4103\/ijdvl.IJDVL_786_17","article-title":"Injection-site reaction to ixekizumab histologically mimicking lupus tumidus: report of two cases","volume":"84","author":"Prieto-Barrios","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101334_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101334_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.xkme.2026.101334_bib22","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.xkme.2026.101334_bib23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1373\/clinchem.2009.141564","article-title":"Mendelian randomization in the era of genomewide association studies","volume":"56","author":"Sleiman","year":"2010","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.xkme.2026.101334_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int J Epidemiol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101334_bib25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/ng.3434","article-title":"Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus","volume":"47","author":"Bentham","year":"2015","journal-title":"Nat Genet"},{"issue":"16","key":"10.1016\/j.xkme.2026.101334_bib26","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/0008-5472.CAN-20-0985","article-title":"LDtrait: an online tool for identifying published phenotype associations in linkage disequilibrium","volume":"80","author":"Lin","year":"2020","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.xkme.2026.101334_bib27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101334_bib28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40257-024-00876-x","article-title":"Efficacy and safety of brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, for palmoplantar pustulosis: 16-week results of a randomized clinical trial","volume":"25","author":"Okubo","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"10235","key":"10.1016\/j.xkme.2026.101334_bib29","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.xkme.2026.101334_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102393","article-title":"Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"18","author":"Parisis","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.xkme.2026.101334_bib31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/ard.57.8.451","article-title":"Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study","volume":"57","author":"Hardy","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xkme.2026.101334_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1238457","article-title":"Interleukin-17 and inflammatory bowel disease: a 2-sample Mendelian randomization study","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.xkme.2026.101334_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clim.2016.04.010","article-title":"T cells and IL-17 in lupus nephritis","volume":"185","author":"Koga","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.xkme.2026.101334_bib34","article-title":"Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus","volume":"11","author":"Koga","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101334_bib35","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.xkme.2026.101334_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000314","article-title":"Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA","volume":"3","author":"Jani","year":"2017","journal-title":"RMD Open"},{"issue":"6649","key":"10.1016\/j.xkme.2026.101334_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(51)93319-3","article-title":"Role of sulphonamides and penicillin in the pathogenesis of systemic lupus erythematosus","volume":"1","author":"Gold","year":"1951","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.xkme.2026.101334_bib38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/ard.58.5.288","article-title":"Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years","volume":"58","author":"Gordon","year":"1999","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.xkme.2026.101334_bib39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/0961203312436861","article-title":"Statin-induced lupus: a case\/non-case study in a nationwide pharmacovigilance database","volume":"21","author":"Moulis","year":"2012","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.xkme.2026.101334_bib40","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-88-5-650","article-title":"Isoniazid induction of antinuclear antibodies. A prospective study","volume":"88","author":"Rothfield","year":"1978","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101334_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-196701000-00001","article-title":"Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus","volume":"46","author":"Alarc\u00f3n-Segovia","year":"1967","journal-title":"Med (Baltim)"},{"issue":"9","key":"10.1016\/j.xkme.2026.101334_bib42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","article-title":"Drug-induced lupus: traditional and new concepts","volume":"17","author":"Vaglio","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.xkme.2026.101334_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xkme.2026.101334_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.xkme.2026.101334_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaad.2023.09.028","article-title":"Association of psoriasis and systemic lupus erythematosus and mediation effects of tumor necrosis factor-\u03b1 inhibitors: a cross-sectional study in the All of Us Research Program","volume":"90","author":"Chen","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:52:06Z","timestamp":1778907126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2590059526000956"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101334","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-17 Inhibitors and the Potential Association of Systemic Lupus Erythematosus","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101334"}}